SA07280637B1 - مضادات أجسام مضادة للانقسام جديدة - Google Patents

مضادات أجسام مضادة للانقسام جديدة Download PDF

Info

Publication number
SA07280637B1
SA07280637B1 SA07280637A SA07280637A SA07280637B1 SA 07280637 B1 SA07280637 B1 SA 07280637B1 SA 07280637 A SA07280637 A SA 07280637A SA 07280637 A SA07280637 A SA 07280637A SA 07280637 B1 SA07280637 B1 SA 07280637B1
Authority
SA
Saudi Arabia
Prior art keywords
antibody
arrangement
cdr
defining
order
Prior art date
Application number
SA07280637A
Other languages
Arabic (ar)
English (en)
Inventor
كورفيا ناتلي
هاآو جون فرنسوا
بي سيدريك
جوتس ليليان
Original Assignee
بيير فابر ميديكامو
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by بيير فابر ميديكامو filed Critical بيير فابر ميديكامو
Publication of SA07280637B1 publication Critical patent/SA07280637B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SA07280637A 2006-11-24 2007-11-24 مضادات أجسام مضادة للانقسام جديدة SA07280637B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation

Publications (1)

Publication Number Publication Date
SA07280637B1 true SA07280637B1 (ar) 2012-04-11

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
SA07280637A SA07280637B1 (ar) 2006-11-24 2007-11-24 مضادات أجسام مضادة للانقسام جديدة

Country Status (27)

Country Link
US (2) US8071730B2 (cg-RX-API-DMAC7.html)
EP (1) EP2074148A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010509931A (cg-RX-API-DMAC7.html)
KR (1) KR20090088878A (cg-RX-API-DMAC7.html)
CN (1) CN101535344B (cg-RX-API-DMAC7.html)
AU (1) AU2007324509B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719323A2 (cg-RX-API-DMAC7.html)
CA (1) CA2670039A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007003357A1 (cg-RX-API-DMAC7.html)
CR (1) CR10788A (cg-RX-API-DMAC7.html)
CU (1) CU23792A3 (cg-RX-API-DMAC7.html)
EC (1) ECSP099341A (cg-RX-API-DMAC7.html)
FR (1) FR2909092B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20125629B (cg-RX-API-DMAC7.html)
GT (1) GT200900126A (cg-RX-API-DMAC7.html)
IL (1) IL198744A0 (cg-RX-API-DMAC7.html)
MA (1) MA30891B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009005293A (cg-RX-API-DMAC7.html)
NI (1) NI200900079A (cg-RX-API-DMAC7.html)
NO (1) NO20092360L (cg-RX-API-DMAC7.html)
NZ (1) NZ576174A (cg-RX-API-DMAC7.html)
RU (1) RU2451689C2 (cg-RX-API-DMAC7.html)
SA (1) SA07280637B1 (cg-RX-API-DMAC7.html)
TN (1) TN2009000194A1 (cg-RX-API-DMAC7.html)
TW (1) TW200829602A (cg-RX-API-DMAC7.html)
UA (1) UA99602C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008062063A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
WO2011053759A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
CN103298489A (zh) * 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
DK3489261T3 (da) 2012-08-24 2020-12-14 Univ California Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
JP7109007B2 (ja) 2016-06-27 2022-07-29 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア がん治療の組み合わせ
WO2018027039A1 (en) 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
SK14812000A3 (sk) * 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
HU229376B1 (en) * 1999-03-11 2013-11-28 Serono Lab Vascular adhesion molecules and modulation of their function
WO2005060457A2 (en) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
JP2008539693A (ja) * 2005-05-12 2008-11-20 オンコセラピー・サイエンス株式会社 抗ｄｓｃ２抗体のエフェクター機能を用いて細胞を障害する方法
CA2650380A1 (en) * 2006-04-28 2007-11-08 Oregon Health & Science University Monoclonal antibodies and their use

Also Published As

Publication number Publication date
GT200900126A (es) 2011-09-02
BRPI0719323A2 (pt) 2014-02-04
CN101535344B (zh) 2013-10-16
RU2451689C2 (ru) 2012-05-27
EP2074148A1 (en) 2009-07-01
CA2670039A1 (en) 2008-05-29
FR2909092A1 (fr) 2008-05-30
US20120156191A1 (en) 2012-06-21
NZ576174A (en) 2012-03-30
AU2007324509A1 (en) 2008-05-29
IL198744A0 (en) 2010-02-17
UA99602C2 (ru) 2012-09-10
CR10788A (es) 2009-06-23
MA30891B1 (fr) 2009-11-02
CL2007003357A1 (es) 2008-04-04
RU2009123409A (ru) 2010-12-27
FR2909092B1 (fr) 2012-10-19
TN2009000194A1 (en) 2010-10-18
MX2009005293A (es) 2009-08-07
WO2008062063A1 (en) 2008-05-29
CN101535344A (zh) 2009-09-16
GEP20125629B (en) 2012-09-10
US8071730B2 (en) 2011-12-06
US20100092455A1 (en) 2010-04-15
ECSP099341A (es) 2009-06-30
JP2010509931A (ja) 2010-04-02
AU2007324509B2 (en) 2013-01-17
NO20092360L (no) 2009-08-11
CU23792A3 (es) 2012-03-15
KR20090088878A (ko) 2009-08-20
HK1132752A1 (en) 2010-03-05
NI200900079A (es) 2010-11-10
TW200829602A (en) 2008-07-16

Similar Documents

Publication Publication Date Title
JP7069261B2 (ja) Ｃｄ７３特異的結合分子及びその使用
SA07280637B1 (ar) مضادات أجسام مضادة للانقسام جديدة
KR102838340B1 (ko) 다중-특이적 항체 및 이들의 제조 및 사용 방법
US12497455B2 (en) Anti-CD3E/BCMA bispecific antibody and use thereof
CN113286634A (zh) 对gucy2c特异性的抗体及其用途
WO2018133842A1 (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
JP2020536109A (ja) Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
MX2012011234A (es) Anticuerpos contra csf-1r.
AU2014317009A1 (en) CD70-binding peptides and method, process and use relating thereto
CN112955548A (zh) 叶酸受体α特异性抗体
CA3207791A1 (en) Anti-cd112r antibody and use thereof
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
CN114341170B (zh) 一种人源化抗vegfr2抗体及其应用
IL321280A (en) Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof
AU2019439345B2 (en) Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof
US20250289901A1 (en) Anti-cd3e/bcma bispecific antibody and use thereof
EP4620973A1 (en) Antibodies targeting cell surface deposited complement protein c3d and use thereof
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
EP4183800A1 (en) Novel sars-cov-2 neutralizing antibodies
JP2025516434A (ja) 抗ｃｄ７３抗体およびその使用
JP2025534397A (ja) 前立腺がんの診断及び早期発症に関して使用されるモノクローナル抗体
CN120623343A (zh) 一种b7-h6单克隆抗体及其应用
HK40089230A (zh) 药物组合物及用途
HK40062048B (zh) 针对密蛋白18a2的抗体及其应用
HK40066232A (zh) 一种人源化抗vegfr2抗体及其应用